Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (762)	12/3/1999 3:19:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

Despite the fact that the issue is immune response to that particular vector... my initial thought back then was that it should give regulation systems some good press--the FDA will increasingly demand Gene Therapy with some measure of control. ARGENT and the Baylor/Valentis geneswitch should have showed up somewhere in the popular press by now, but maybe next year. There may have been some extra enthusiasm on the AAV plays...the Street seems to understand that this is one of the safer vectors...but the public certainly does not have an appreciation for the hybrid Ad/AAV systems...Heck, words like promoter and enchancer didn't even show up in my vocabulary til this past summer--and I don't think I can use them in a sentence, heheh. I think there was a short subthread on the Gene Therapy thread at the time of the death. That is also about the time the guys on the Ariad Yahoo thread starting using expressions like "frought with peril", but that settled down pretty quick after they shook me out (not that it was intentional mind you) and the stock make it's spectacular bottom.